Healthcare Industry News: Halcyon
News Release - December 6, 2017
Varian Halcyon Treatment System Receives ANVISA Registration in BrazilNew advanced cancer treatment system from Varian now available to cancer centers in Brazil
PALO ALTO, Calif., Dec. 6, 2017 -- (Healthcare Sales & Marketing Network) -- Further expanding the global availability of its new device for cancer treatment, Varian (NYSE: VAR) today announced the Halcyon™ system has received ANVISA registration in Brazil. This registration allows Varian to market this new system in Brazil. Halcyon simplifies and enhances virtually every aspect of image-guided volumetric intensity modulated radiotherapy (IMRT), and is well suited to treat a majority of cancer patients, offering advanced treatments for prostate, breast, head & neck, and many other forms of cancer.
"Halcyon is engineered to revolutionize the clinical workflow and advance cost-effective cancer care worldwide," said Kolleen Kennedy, president of Varian's Oncology Systems business. "With ANVISA registration, clinicians in Brazil now have access to this new technology and we look forward to continuing our close collaboration with them in the global fight against cancer."
Halcyon is an advanced system that was designed to improve patient comfort, simplify operations, and shorten the time from installation to first-treatment without sacrificing quality. Patients benefit from its quiet operating environment, which is up to 2x quieter than other systems. Additionally, Halcyon has a low couch height for easy patient access, and soft indirect ambient lighting in the gantry opening.
Featuring a 100cm gantry opening, which is larger than those on standard CT machines, Halcyon is capable of rotations 4x faster than c-arm gantries for rapid imaging and treatment. The system is also capable of fast and sharp volumetric imaging in as little as 15 seconds. With Halcyon treatments, a complex image guided IMRT plan is clinically accelerated compared to those delivered on traditional devices.
Operationally, Halcyon features a streamlined workflow that only requires nine steps from the start to the end of treatment compared to up to more than 30 steps with older technologies. To assist in the reduction of time and construction costs from installation to first patient treatment, Halcyon comes pre-commissioned, requires less shielding than traditional systems, can fit in a vault as small as 5.9 meters (19.68 feet) x 5.539 meters (18.17 feet) x 2.743 meters (8.99 feet) high and can be installed in two weeks or less.
For more information on Halcyon, visit www.varian.com/Halcyon.
Varian focuses energy on saving lives and is the world's leading manufacturer of medical devices and software for treating and managing cancer. Headquartered in Palo Alto, California, Varian employs approximately 6,500 people around the world. For more information, visit http://www.varian.com and follow @VarianMedSys on Twitter.
Source: Varian Medical Systems
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.